ChromaDex Corporation (NASDAQ:CDXC) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Rob Fried – Chief Executive Officer Kevin Farr – Chief Financial Officer Brianna Gerber – Vice President of Finance, Investor Relation Frank Jaksch – Co-Founder and Executive Chairman Conference Call Participants Brian W. Nagel – Oppenheimer & Co. Mitchell Pinheiro – Sturdivant & Co. Sean McGowan – ROTH Capital Partners Bill Dezellem – Tieton Capital Management Operator Ladies and gentlemen, tha ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) | --- | --- | --- | |----------------------------------------------------------------------------------|----------------------------|-------------------------------------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number 001-37752 CHROMADEX CORPORATION (Exact name of Registrant as specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorp ...

Financial Data and Key Metrics Changes - Full year net sales were $67.4 million, a 14% increase year-over-year [13] - Tru Niagen net sales were $56.7 million, a 20% increase year-over-year [13] - Gross margins were 61.5%, a 200 basis point increase versus last year [13] - Total operating loss was $5.3 million in Q4 2021, compared to $8.8 million in Q3 2021 [14][46] - Net loss attributable to common stockholders for Q4 2021 was $5.3 million or a loss of $0.08 per share, compared to a net loss of $8.9 million or a loss of $0.13 per share for Q3 2021 [46] Business Line Data and Key Metrics Changes - Tru Niagen net sales in Q4 2021 were down 5% sequentially [36] - Niagen ingredient sales were up 53% versus the prior quarter, driven by sales to Life Extension and a shipment to H&H Group [40] - E-commerce sales grew by 21% year-over-year [31] Market Data and Key Metrics Changes - Sales to Monte Cana were impacted by COVID-19 restrictions in Australia [37] - Watsons sales were $2.2 million in Q4 2021 compared to $2.6 million in Q3 2021 [38] - E-commerce business was up 6% sequentially, driven by promotions in the U.S. and China [39] Company Strategy and Development Direction - The company launched Tru Niagen in 3,800 Walmart stores, marking its first mass retail launch in the U.S. [9] - Partnerships with Sinopharm Xingsha and H&H Group were established to grow the Tru Niagen cross-border business and ingredient business [9][10] - The focus is on translating scientific research into marketing messages related to aging, heart health, and cellular health [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the market opportunity for Tru Niagen, despite challenges from COVID-19 and increased customer acquisition costs [64] - The company expects 15% to 20% growth in net sales for 2022, with continued investment in marketing and brand awareness [52][51] - Management noted that the majority of legal spending related to litigation is behind them, allowing for reinvestment in brand building [59] Other Important Information - The ChromaDex External Research Program (CERP) achieved its 100th published peer-reviewed study on Niagen [11] - The company has over 40 patents on NR and other NAD precursors, with a new patent granted that protects the manufacturing process through 2037 [12] Q&A Session Summary Question: Can you talk about marketing claims and outcomes on work being done now? - Management stated that they look at the total body of evidence to support claims, with clinical studies carrying the most weight [57] Question: What do you anticipate as legal expenses for 2022? - Legal expenses are expected to be around $4 million in 2022, with ongoing litigation costs anticipated to be less than $1 million each [58] Question: Why is the 2022 sales guidance below expectations? - Management indicated that macroeconomic changes and increased customer acquisition costs have led to a more conservative outlook [62][64] Question: What is happening with Nestle? - Management noted that Nestle is interested in expanding their relationship, but it must be done in a way that optimizes shareholder interests [74]

Financial Performance - Total net sales for Q4 2021 were $178 million, a 15% increase year-over-year and a 3% increase compared to Q3 2021[51] - Tru Niagen® net sales reached $141 million in Q4 2021, representing a 14% year-over-year growth, but a 5% sequential decline compared to Q3 2021[51] - The company maintained a strong gross margin of 612% in Q4 2021, slightly up from 611% in Q3 2021 and 610% in Q4 2020[51,37] - The net loss for Q4 2021 was $(53) million, or $(008) per share, compared to a net loss of $(61) million, or $(010) per share, in Q4 2020[51] - Adjusted EBITDA, excluding total legal expense, showed a loss of $(18) million in Q4 2021, compared to a loss of $(11) million in Q4 2020[51] - Full year 2021 net sales reached $67449 million, a 14% increase compared to 2020[46] Sales Mix - E-commerce accounted for 63% of net sales in Q4 2020 and 61% in Q4 2021[23] - Niagen® ingredient sales represented 14% of net sales in both Q4 2020 and Q4 2021[23] - Tru Niagen® net sales accounted for 79% of total net sales in Q4 2021, compared to 85% in Q3 2021[23] - Niagen®-related net sales made up 94% of total net sales in Q4 2021, slightly down from 95% in Q3 2021[23] Expenses - Selling and marketing expenses accounted for 487% of net sales in Q4 2021, compared to 409% in Q4 2020 and 417% in Q3 2021[51,37] - General and administrative expenses were $65 million in Q4 2021, a decrease of $(47) million sequentially and $(18) million year-over-year, primarily due to lower legal expenses[51]

ChromaDex Corporation (NASDAQ:CDXC) Q3 2021 Results Earnings Conference Call November 4, 2021 4:30 PM ET Company Participants Brianna Gerber - Vice President of Finance and Investor Relations Rob Fried - Chief Executive Officer Frank Jaksch Jr. - Co-Founder and Executive Chairman of the Board Kevin Farr - Chief Financial Officer Fadi Karam - Chief Marketing Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Brian Nagel - Oppenheimer & Co. Mitchell Pinheiro - Sturdivant & Co., Inc. Ragh ...

Financial Performance - Net sales for the three months ended September 30, 2021, were $17.3 million, a 22.5% increase from $14.2 million in the same period of 2020[142] - Net loss for the three months ended September 30, 2021, was $8.9 million, compared to a net loss of $4.2 million for the same period in 2020[142] - Basic and diluted loss per common share for the three months ended September 30, 2021, was $(0.13), compared to $(0.07) for the same period in 2020[142] - For the nine months ended September 30, 2021, net sales were $49.7 million, up from $43.8 million in the same period of 2020, representing a 9.5% increase[142] - Net loss for the nine months ended September 30, 2021, was $21.8 million, compared to a net loss of $13.8 million for the same period in 2020[142] - Total net sales increased by approximately 22% and 13% for the three and nine months ended September 30, 2021, compared to the same periods in 2020, reaching $17,308 thousand and $49,690 thousand respectively[143] Cash and Financing - The company has approximately $33.1 million in cash and cash equivalents as of September 30, 2021, which is expected to support projected operating plans for at least the next twelve months[138] - The company entered into a Securities Purchase Agreement on February 20, 2021, resulting in proceeds of $24.9 million from the sale of approximately 3.8 million shares of common stock[136] - Net cash provided by financing activities was approximately $36.0 million for the nine months ended September 30, 2021, compared to approximately $7.5 million for the same period in 2020[167] - The company received proceeds of $24.9 million from financing on February 23, 2021, net of offering costs[160] - The company has a line of credit of up to $7.0 million from Western Alliance Bank, which is expected to be sufficient for projected operating plans for at least the next twelve months[161] Inventory and Supply Chain - The company is committed to purchase approximately $18.0 million of total inventory under the Grace Manufacturing Agreement between January 1, 2022, and December 31, 2022[140] - The company has experienced delays in its supply chain due to global components and packaging shortages but has maintained adequate inventory to meet current demands[132] Sales and Marketing - The company began distributing Tru Niagen® in over 3,800 U.S. Walmart™ stores starting in June 2021, marking a significant expansion in its retail operations[131] - TRU NIAGEN® sales in the consumer products segment increased by approximately $1.9 million, or 21%, for the three months ended September 30, 2021, and $5.7 million, or 23%, for the nine months ended September 30, 2021 compared to the same periods in 2020[143] - Sales and marketing expenses for the consumer products segment increased by 41% for the three months and 37% for the nine months ended September 30, 2021, driven by direct marketing efforts[148] Expenses - Gross profit for the consumer products segment was $9.5 million and $27.6 million for the three and nine months ended September 30, 2021, representing a 27% increase for both periods compared to 2020[147] - Total cost of sales was $6,730 thousand for the three months and $19,068 thousand for the nine months ended September 30, 2021, with cost of sales as a percentage of net sales remaining stable at 39% for the three months and 38% for the nine months[145] - Research and development expenses increased by 18% for the three months ended September 30, 2021, totaling $996 thousand, and by 10% for the nine months, totaling $2,787 thousand compared to the same periods in 2020[151] - General and administrative expenses rose by 70% for the three months ended September 30, 2021, amounting to $11,202 thousand, and by 33% for the nine months, totaling $29,881 thousand, primarily due to increased legal expenses[152] Operational Challenges - The ingredients segment experienced a gross profit decrease of 35% for the nine months ended September 30, 2021, totaling $2.6 million compared to $4.0 million in 2020[147] - The analytical reference standards and services segment saw a 95% decrease in gross profit for the three months ended September 30, 2021, compared to the same period in 2020[147] - The company incurred aggregate losses of approximately $163.6 million from inception through September 30, 2021, primarily due to operational development and intellectual property protection expenses[158] - Net cash used in operating activities for the nine months ended September 30, 2021 was approximately $19.2 million, an increase from approximately $10.6 million for the same period in 2020[164] - The company expects its operating cash flows to fluctuate significantly due to various factors including shipment timetables and inventory management[165] Tax and Compliance - The company maintained a full valuation allowance against the entire deferred income tax balance, resulting in an effective tax rate of approximately 0% for the three and nine months ended September 30, 2021[153] - Amortization expense of right of use assets for the nine months ended September 30, 2021 was approximately $0.4 million, compared to $0.3 million for the same period in 2020[157] - The company identified a material weakness in internal control over financial reporting, which is being addressed and expected to be remediated by the end of 2021[174]

ChromaDex Earnings Conference Call Second Quarter 2021 Rob Fried Chief Executive Officer Frank Jaksch Co-Founder / Executive Chairman Kevin Farr Chief Financial Officer Nasdaq: CDXC | August 3, 2021 1 SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Forward-l ...

Financial Data and Key Metrics Changes - ChromaDex reported total net sales of $17.7 million for Q2 2021, representing a 21% sequential increase and a 16% year-over-year increase compared to Q2 2020 [8][23][30] - Adjusted EBITDA, excluding legal expenses, was $640,000, marking a $1.3 million improvement from the previous quarter [8][23] - Gross margins decreased to approximately 61.1%, down from 62.9% in Q1 2021, attributed to a higher mix of B2B sales [10][26][31] Business Line Data and Key Metrics Changes - Tru Niagen net sales increased by 24% sequentially, driven by strong sales to Watsons, which amounted to $2.9 million in Q2 2021 [24][30] - E-commerce sales grew by 11% sequentially and 31% year-over-year, benefiting from Amazon Prime Day sales [9][25] - Sales of Niagen ingredients were down 36% year-over-year, primarily due to the loss of a customer, while other ingredient sales decreased by 74% [30] Market Data and Key Metrics Changes - Sales to Watsons increased significantly following a temporary supply chain disruption in the previous quarter [9][24] - The Hong Kong market continues to face challenges with store traffic down year-over-year, impacting overall sales despite a loyal customer base [25][37] Company Strategy and Development Direction - ChromaDex is focused on expanding its presence in mass retail, with the launch of Tru Niagen in 3,800 Walmart stores [12][34] - The company plans to increase investments in marketing and brand awareness, particularly targeting Walmart consumers [41][63] - Continued commitment to R&D investments to maintain leadership in the NAD market, with a focus on nicotinamide riboside and its health benefits [22][64] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future growth, citing strong consumer demand and the potential for increased sales through new partnerships [13][34] - The company anticipates that sales growth will accelerate in the fourth quarter, driven by new product launches and marketing campaigns [34][35] - Management acknowledged ongoing challenges due to COVID-19, particularly in the Hong Kong market, but remains confident in the brand's resilience [25][37] Other Important Information - ChromaDex has completed 13 clinical trials and has nearly 40 more in progress, reinforcing the scientific foundation of its products [11][22] - The company is actively involved in research related to various health claims, including cognitive function and muscle health, which may lead to new product claims [67] Q&A Session Summary Question: Impact of COVID on Tru Niagen sales - Management noted fluctuations in sales due to COVID, with store traffic in Hong Kong still below pre-pandemic levels, affecting overall demand [37] Question: Marketing spend outlook - Management indicated an increase in marketing spend to support brand building and Walmart initiatives, with a shift towards traditional media [39][41] Question: Walmart distribution and product placement - Management confirmed that Tru Niagen is in the majority of Walmart stores, with ongoing efforts to ensure product placement and monitor sales performance [54][56] Question: E-commerce growth and customer retention - Management reported strong retention rates and an increase in new customer acquisition, contributing to e-commerce growth [71] Question: R&D investments and studies - Management highlighted ongoing investments in R&D to support the development of new products and health claims, particularly around nicotinamide riboside [64][66]

Financial Performance - Total net sales increased by approximately 16% for the three months ended June 30, 2021, and 9% for the six months ended June 30, 2021, compared to the same periods in 2020[142] - E-commerce sales for TRU NIAGEN® increased approximately $2.5 million, or 31%, for the three months ended June 30, 2021, and $3.9 million, or 24%, for the six months ended June 30, 2021, compared to the same periods in 2020[145] - The analytical reference standards and services segment saw a 20% increase in sales for the six months ended June 30, 2021, compared to the same period in 2020[143] - Consumer products segment gross profit increased by 33% to $9.8 million for the three months ended June 30, 2021, and by 27% to $18.1 million for the six months ended June 30, 2021 compared to the same periods in 2020[149] - Total gross profit for the company increased by 19% to $10.8 million for the three months ended June 30, 2021, and by 15% to $20.0 million for the six months ended June 30, 2021 compared to the same periods in 2020[149] Losses and Expenses - The net loss for the three months ended June 30, 2021, was $5.6 million, compared to a net loss of $3.7 million for the same period in 2020[142] - Basic and diluted loss per common share for the three months ended June 30, 2021, was $(0.08), compared to $(0.06) for the same period in 2020[142] - General and administrative expenses increased by 32% to $9.1 million for the three months ended June 30, 2021, and by 18% to $18.7 million for the six months ended June 30, 2021 compared to the same periods in 2020, primarily due to increased legal expenses[153] - Total sales and marketing expenses increased by 26% to $6.2 million for the three months ended June 30, 2021, and by 33% to $12.5 million for the six months ended June 30, 2021 compared to the same periods in 2020[150] - Research and development expenses increased by 12% to $1.0 million for the three months ended June 30, 2021, and by 5% to $1.8 million for the six months ended June 30, 2021 compared to the same periods in 2020[152] - The ingredients segment gross profit decreased by 52% to $0.8 million for the three months ended June 30, 2021, and by 50% to $1.6 million for the six months ended June 30, 2021 compared to the same periods in 2020[149] - The company incurred aggregate losses of approximately $154.8 million from inception through June 30, 2021, primarily due to operational development and litigation-related expenses[159] Cash and Financing - As of June 30, 2021, the company had approximately $38.8 million of cash and cash equivalents on hand, with an additional line of credit of up to $7.0 million available[140] - The company received proceeds of $24.9 million from financing on February 23, 2021, and $1.9 million in June 2021 under the ATM facility[161] - Net cash used in operating activities for the six months ended June 30, 2021 was approximately $13.3 million, an increase from approximately $6.8 million for the same period in 2020[165] - Net cash provided by financing activities was approximately $35.7 million for the six months ended June 30, 2021, significantly up from approximately $7.0 million for the same period in 2020[168] - The company expects operating cash flows to fluctuate significantly in future periods due to various factors including operating results and inventory management[166] Operational Challenges - The company has experienced delays in the supply chain due to global packaging shortages but has addressed these issues in the second quarter of 2021[134] - A material weakness in internal control over financial reporting was identified, affecting the disclosure of a potential loss of approximately $1.6 million[174] - The company is in the process of addressing the identified material weakness and expects remediation to be completed by the end of 2021[175] - As of June 30, 2021, the company's disclosure controls and procedures were deemed not effective due to the material weakness[175] - No changes in internal control over financial reporting occurred that materially affected the company's internal control during the second fiscal quarter[177] Other Financial Information - Cost of sales as a percentage of net sales decreased by 2% and 3% for the three and six months ended June 30, 2021, respectively, compared to the same periods in 2020[147] - There were no material changes in contractual obligations during the six months ended June 30, 2021[169] - The company had no material off-balance sheet arrangements during the six months ended June 30, 2021[170] - The company maintains a full valuation allowance against deferred tax assets, resulting in an effective tax rate of approximately 0% for the three and six months ended June 30, 2021[155]